STAAR Surgical Company (STAA)
- Previous Close
47.82 - Open
46.90 - Bid 46.79 x 100
- Ask 46.94 x 100
- Day's Range
45.42 - 47.05 - 52 Week Range
26.66 - 73.13 - Volume
347,532 - Avg. Volume
722,466 - Market Cap (intraday)
2.304B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
109.05 - EPS (TTM)
0.43 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
48.28
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
www.staar.com1,056
Full Time Employees
December 29
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STAA
Performance Overview: STAA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAA
Valuation Measures
Market Cap
2.30B
Enterprise Value
2.12B
Trailing P/E
109.05
Forward P/E
163.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.19
Price/Book (mrq)
5.97
Enterprise Value/Revenue
6.57
Enterprise Value/EBITDA
63.78
Financial Highlights
Profitability and Income Statement
Profit Margin
6.62%
Return on Assets (ttm)
4.09%
Return on Equity (ttm)
5.91%
Revenue (ttm)
322.42M
Net Income Avi to Common (ttm)
21.35M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
220.73M
Total Debt/Equity (mrq)
9.28%
Levered Free Cash Flow (ttm)
-2.79M
Research Analysis: STAA
Company Insights: STAA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: STAA
STAA: What does Argus have to say about STAA?
STAAR SURGICAL CO has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetSTAA: Lowering target price to $41.00
STAAR SURGICAL CO has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetSTAA: Raising target price to $43.00
STAAR SURGICAL CO has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetSTAA: Raising target price to $36.00
STAAR SURGICAL CO has an Investment Rating of SELL; a target price of $36.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target